Live Breaking News & Updates on Clinical oncology annual meeting

Stay informed with the latest breaking news from Clinical oncology annual meeting on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical oncology annual meeting and stay connected to the pulse of your community

Novel Drug Combo Fast Tracked for Advanced Breast Cancer Subset

Zotatifin plus Faslodex and Verzenio was granted as a Fast Track Designation for the treatment of ER-positive, HER2-negative advanced or metastatic breast cancer.

United-states , San-antonio , Texas , American , Steve-worland , American-society-of-clinical-oncology-annual-meeting , Drug-administration , Fast-track-designation , Track-designations , Fast-track , Clinical-oncology-annual-meeting , San-antonio-breast-cancer-symposium

eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

13.11.2023 - Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS) Topline results from Phase 2b KICKSTART ...

Russia , United-states , Ukraine , American , Kevin-gardner , Jennifer-caswell-jin , Christian-curtis , Steve-worland , Christopherm-calabrese , Mike-tattory , Development-rd-expenses , Roberth-lurie-comprehensive-cancer-center

Form 10-Q Cullinan Oncology, Inc. For: Sep 30

Form 10-Q Cullinan Oncology, Inc. For: Sep 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Macau , Hong-kong , Japan , Massachusetts-institute-of-technology , Massachusetts , United-states , Taiwan , China , Delaware , Cambridge , Cambridgeshire , United-kingdom

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low

Planned Subgroup Analysis of RAMP 201 Data Showed Combination Demonstrated Robust Efficacy in Recurrent LGSOC Regardless of Number and Class of Prior Therapies Including After Poor Response to Prior TherapyLate-Breaking Abstract Featured as an Oral Presentation during a Plenary Session at the Annual Global Meeting o...

Seoul , Soult-ukpyolsi , South-korea , United-states , American , Ryan-porter , Lisa-buffington , Rachel-grisham , Company-annual-report-on-form , Amgen , Secura-bio-inc , Chugai-pharmaceutical-co-ltd

Verastem Oncology (VSTM) Reports Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

Verastem Oncology (VSTM) Reports Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Seoul , Soult-ukpyolsi , South-korea , American , Rachel-grisham , Drug-administration , Verastem-oncology , Annual-global-meeting , International-gynecologic-cancer-society , Section-head , Ovarian-cancer

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript

Operator: Hello, and thank you for standing by. Welcome to the Allogene Therapeutics Third Quarter 2023 Conference Call.

United-states , Canada , Australia , American , Michael-yee , Tyler-van-baron , Christine-cassiano , Brian-cheng , Zachary-roberts , Jack-allen , Marcelo-pasquini , David-chang

Merck - KEYTRUDA Significantly Improved Overall Survival versus Placebo as Adjuvant Therapy for Certain Patients with Renal Cell Carcinoma Following Nephrectomy

RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, met its key secondary...

Japan , United-states , Canada , American , Julie-cunningham , Peter-dannenbaum , Michael-mcardle , European-society-for-medical-oncology , Exchange-commission , European-union , Data-monitoring-committee , American-society-of-clinical-oncology-annual-meeting

KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy

KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan , United-states , Canada , American , Peter-dannenbaum , Michael-mcardle , Julie-cunningham , Damini-chokshi , Youtube , Instagram , Statement-of-merck-co-inc , Merck-research-laboratories

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Germany , United-states , Heidelberg , Baden-wüberg , France , Chicago , Illinois , Mannheim , Denmark , Coindre , Auvergne , Anneberg

KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Th

KEYTRUDA is the first therapy to show a statistically significant improvement in OS as adjuvant therapy in patients with RCC at a higher risk of recurrence following nephrectomyNew OS results build on the significant disease-free survival benefit previously reported from the KEYNOTE-564 trialRAHWAY, N.J.--(BUSINESS...

Japan , Canada , United-states , American , Peter-dannenbaum , Julie-cunningham , Michael-mcardle , Damini-chokshi , Merck-research-laboratories , American-society-of-clinical-oncology-annual-meeting , Data-monitoring-committee , European-society-for-medical-oncology